Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States

由 Hernandez, Luis, Shah, Anshul, Zhao, Qi, Milentijevic, Dejan, Kharat, Akshay
發表在 Am Health Drug Benefits (2020)

Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

由 Burudpakdee, Chakkarin, Shah, Anshul, Joish, Vijay N., Divers, Christine H., Yaldo, Avin
發表在 Am Health Drug Benefits (2014)

Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion

由 Bradshaw, Steven E., Gala, Smeet, Nanavaty, Merena, Shah, Anshul, Mwamburi, Mkaya, Kefalas, Panos
發表在 BMC Ophthalmol (2016)

Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

由 Hernandez, Luis, Kuwabara, Hiroyo, Shah, Anshul, Yamabe, Kaoru, Burnett, Heather, Fahrbach, Kyle, Koufopoulou, Maria, Iwakiri, Ryuichi
發表在 Pharmacoeconomics (2019)